Publications
Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies
1 April 2017
The 2016 meeting of the HTAi Asia Policy Forum meeting was held in Kuala Lumpur, 17th -18th November 2016. The topic of the meeting was: Assessing…
How can HTA meet the needs of health system and government decision makers?
4 January 2017
The 2015 meeting of the HTAi Asia Policy Forum meeting was held in Singapore, 29th -30th October 2015. The topic of the meeting was: How can…
Transferability of HTA
4 January 2017
The second HTAi Asia Policy Forum meeting (2014) was held in Manilla, 10th -11th June 2014. The topic of the meeting was: Transferability of HTA. This…
HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers?
4 January 2017
The HTAi Asia Policy Forum meeting 2013 was held in Seoul, 13th -14th June 2013. This was the first of several annual meetings of the HTAi…
Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
1 March 2017
This report presents an analysis of the significant clinical potential of gene therapy and the unique challenges in developing and evaluating evidence on their effectiveness and…
Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries
1 March 2017
The European Commission’s (EC) Orphan Medicinal Products Regulation intended to incentivise the research, development and marketing of new treatments for rare and chronically disabling or life-threatening…
Comparing the UK EQ-5D-3L and the English EQ-5D-5L Value Sets
1 March 2017
Three EQ-5D value sets (the EQ-5D-3L, crosswalk and EQ-5D-5L) are now available for cost utility analysis in the UK and/or England. The value sets’ characteristics differ,…
What is the Normative Basis for Selecting the Measure of ‘Average’ Preferences for Use in Social Choices?
1 February 2017
The aim of this paper is to consider what normative arguments might exist for advocating the use of any given measure of the average in the…
Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
1 February 2017
In 2016 the University of York undertook a review exercise to determine whether NICE’s existing methods and processes are appropriate for assessment of regenerative medicines. The…